Rani Therapeutics Holdings Inc
NASDAQ:RANI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Feitian Technologies Co Ltd
SZSE:300386
|
CN |
Rani Therapeutics Holdings Inc
Cash from Operating Activities
Rani Therapeutics Holdings Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Rani Therapeutics Holdings Inc
NASDAQ:RANI
|
Cash from Operating Activities
-$18.7m
|
CAGR 3-Years
26%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Operating Activities
$24.5B
|
CAGR 3-Years
6%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Operating Activities
$14.2B
|
CAGR 3-Years
3%
|
CAGR 5-Years
0%
|
CAGR 10-Years
21%
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Operating Activities
$11.7B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Operating Activities
$16.5B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Operating Activities
$16.8B
|
CAGR 3-Years
30%
|
CAGR 5-Years
21%
|
CAGR 10-Years
19%
|
|
Rani Therapeutics Holdings Inc
Glance View
Rani Therapeutics Holdings, Inc. operates as a clinical stage bio-therapeutics company providing technologies to enable the development of orally administered biologics. The company is headquartered in San Jose, California and currently employs 114 full-time employees. The company went IPO on 2021-07-30. The Company’s technologies enable the development of orally administered biologics. The firm has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which delivers any drug, including molecules, such as peptides, proteins and antibodies. The RaniPill capsule delivers up to a three micrograms (mg) dose of the drug with high bioavailability. Its capsule includes a coating that is designed to withstand stomach acid but dissolves in the jejunum portion of the small intestine. The Company’s product candidate RaniPill capsule is in Phase I clinical trial. The Company’s RaniPill capsule is delivering a variety of biological therapeutics. Its pipeline includes core product candidate programs, such as RT-101, RT-105, RT-102, RT-109 and RT-110. The firm manufactures and assembles RaniPill capsules at its facilities in San Jose and Milpitas, California.
See Also
What is Rani Therapeutics Holdings Inc's Cash from Operating Activities?
Cash from Operating Activities
-18.7m
USD
Based on the financial report for Dec 31, 2025, Rani Therapeutics Holdings Inc's Cash from Operating Activities amounts to -18.7m USD.
What is Rani Therapeutics Holdings Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-5%
Over the last year, the Cash from Operating Activities growth was 47%. The average annual Cash from Operating Activities growth rates for Rani Therapeutics Holdings Inc have been 26% over the past three years , -5% over the past five years .
